A phase II study of subcutaneous bevacizumab for recurrent glioblastoma: Roadblocks and promises.

• DOI: 10.1200/jco.2018.36.15_suppl.e14089
• Publication Date: 2018-09-05T14:20:28Z
• Authors: Joseph Quillin; William L. Read
• Keywords: Clinical endpoint; Tumor progression

e14089 Background: Bevacizumab is a VEGF inhibitor currently utilized in its intravenous formulation to treat recurrent glioblastoma. has been demonstrated slow tumor growth and prolong progression free survival. Monoclonal antibodies are effective both subcutaneous (subq) IV formulations. Providing drugs for subq self-administration, akin insulin or heparin, not only empowers the patient their disease conveniently at home, but also diminishes burden placed upon support system. Methods: Eligible patients had history of high grade glioma with either radiographic pseudoprogression that required dose steroid administration. Because bevacizumab indicated GBM, we intended bill insurance drug administration, which would be done by patient. The primary endpoint was response. Responders continue 3 week cycles treatment until there progression, toxicity, lack benefit. Results: were enrolled this study over 2 years. Patient 1 no response after weeks then changed bevacizumab, produced separate region outside initial XRT field weeks. They simultaneous regression contrast enhancement original radiation field. Both these changes persisted switch bevacizumab. good maintained on therapy 23 Logistical problems encountered billing given intravenously requiring us take them off despite continuing do well. Conclusions: This first phase II trial GBM. Administration through route well-tolerated convenient patients. One an excellent sustained Unfortunately, could unbundle charge from logistical challenge necessitated closure.